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Short Report: Epidemiology
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Abstract
Aims To assess the diagnostic accuracy of four undiagnosed Type 2 diabetes mellitus risk scores accounting for erectile
dysfunction status.
Methods This was a population-based cross-sectional study. Type 2 diabetes was defined according to a oral glucose
tolerance test and self-reported physician diagnosis. Erectile dysfunction was defined according to the answer to the
question, ‘Have you had difficulties obtaining an erection in the last 6 months?’ (yes/no). The risk scores used were the
FINDRISC, LA-FINDRISC, American Diabetes Association score and the Peruvian Risk Score. A Poisson regression
model was fitted to assess the association between Type 2 diabetes and erectile dysfunction. The area under the receiver-
operating characteristic curve was estimated overall and by erectile dysfunction status.
Results A total of 799 men with a mean (SD) age of 48.6 (10.7) years were included in the study. The overall prevalence
of Type 2 diabetes was 9.3%. Compared with healthy men, men with Type 2 diabetes had 2.71 (95% CI 1.57–4.66)
higher chances of having erectile dysfunction. Having excluded men aware of Type 2 diabetes status (N=38), the area
under the receiver-operating characteristic curve of three of the risk scores (not the American Diabetes Association score)
improved among those who had erectile dysfunction in comparison with those who did not; for example, the area under
the receiver-operating characteristic curve of the LA-FINDRISC score was 89.6 (95% CI 78.7–99.9) in men with erectile
dysfunction and 76.5 (95% CI 68.5–84.4) overall.
Conclusions In a population-based study, erectile dysfunction was more common in men with Type 2 diabetes than in
the otherwise healthy men. Screening for erectile dysfunction before screening for Type 2 diabetes seems to improve the
accuracy of well-known risk scores for undiagnosed Type 2 diabetes.
Diabet. Med. 35, 1538–1543 (2018)
Introduction
The prevalence of Type 2 diabetes has increased globally in
recent decades and has increased faster in low- and middle-
income countries where screening, diagnostic and treatment
resources are scarce [1]. Furthermore, costs associated with
Type 2 diabetes are likely to increase even if its prevalence
decreases [2], which would make it harder for low- and
middle-income countries to secure diabetes care for those
diagnosed with Type 2 diabetes and for people at high risk of
the disease. In this context, finding new methods or
approaches to improve the identification of high-risk indi-
viduals is increasingly important. Studying factors associated
with Type 2 diabetes and risk factors is the basis for
identifying the characteristics of those people who would
most benefit from Type 2 diabetes screening.
Type 2 diabetes has been extensively associated with
erectile dysfunction (ED), with a global prevalence of 50%
in men with Type 2 diabetes [3]; however, there have been
few studies on how this seemingly important associated factor
can be used to improve Type 2 diabetes screening. The aim of
the present study, therefore, was to determine whether the
diagnostic accuracy of risk scores for undiagnosed Type 2
diabetes (e.g. FINDRISC [4]) improves according to ED
status in a population-based sample in Peru. The hypothesis
tested was that a risk score for undiagnosed Type 2 diabetes
would discriminate better had we known that ED was
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present. This would further support ED screening in middle-
aged men as a first approach to improving the chances of
successfully diagnosing Type 2 diabetes. This approach
would be particularly relevant in resource-limited settings
where more expensive or even unavailable diagnostic pro-
duces need to be used wisely.
Participants and methods
Study design and setting
This was a cross-sectional analysis of a population-based
study conducted in Tumbes, northern Peru. Tumbes has a
population of 240 590 people (in 2016), of whom at least
10% are considered poor, and the overall life expectancy is
74.7 years [5]. Notably, the prevalence of Type 2 diabetes in
Tumbes exceeds the national average [6].
Study population
Using a recent census of the study area, participants were
selected using a sex-stratified single-stage random sampling
method. Men aged 30–69 years, capable of giving informed
consent and without physical disabilities preventing them
from anthropometric evaluation, were eligible for the present
study. One individual per household was included.
Variables
The outcome of interest was Type 2 diabetes, defined
according to self-reported physician diagnosis or oral glucose
tolerance test criteria: fasting glucose level ≥7.0 mmol/l
(≥126 mg/dl) or 2-h plasma glucose ≥11.1 mmol/l (≥200 mg/
dl) [7]. The Cobas Modular Platform automated analyser
with Roche Diagnostics reagents was used.
The exposure of interest was ED, defined as a positive
answer to the question: ‘During the past 6 months, have you
had difficulties obtaining an erection?’. This question was
based on the Survey of Autonomic Symptoms in people with
Type 2 diabetes [8].
Four risk scores for undiagnosed Type 2 diabetes were
used: FINDRISC [4], LA-FINDRISC [9], the American
Diabetes Association (ADA) score [7], and the Peruvian Risk
Score [10]. Variables to inform these risk scores were
assessed using questionnaires (e.g. physical activity) or
anthropometric assessment (e.g. waist circumference, weight
and height).
Other collected variables included: an assets index based
on facilities and goods owned by the household (numeric and
in tertiles); smoking status (no, occasionally and daily);
alcohol consumption (never, once or less per month, and
more than once per month). In addition, the Alcohol Use
Disorders Identification Test (AUDIT) was used (threshold
set at 8 points), depression was assessed using the Patient
Health Questionnaire, with a threshold set at 10 points [11],
physical activity was assessed using the International Physical
Activity Questionnaire, and blood pressure was measured
three times (the average of the last two values was used) after
a 5-min resting period (OMRON HEM-780, OMRON
Healthcare, Lake Forest, IL, USA). Hypertension was defined
as a blood pressure ≥140/90 mmHg or self-reported physi-
cian diagnosis or currently receiving anti-hypertensive med-
ication. Data collection was conducted by trained field
workers.
Statistical analysis
Statistical analysis was conducted on STATA 13.0 for Win-
dows (StataCorp, College Station, TX, USA). Absolute and
relative frequencies were used to describe categorical vari-
ables, which were compared using the chi-squared test.
Means and SD values were used to summarize numerical
variables, which were compared against categorical variables
with Student’s t-test. A regression model was fitted to study
the association between Type 2 diabetes and ED; the Poisson
family [12] and robust standard errors were specified. A
crude and adjusted model were fitted, the latter accounting
for age (numeric variable), assets index (numeric variable),
BMI (numeric variable), smoking status, physical activity
(numeric variable), alcohol consumption (AUDIT) and
depression (raw score). These estimates are presented as
prevalence ratios with 95% CIs. The area under the receiver-
operating characteristic curve (AUC) for each risk score was
estimated with the roctab command, both overall and
stratified by ED status.
Ethics
All participants provided signed, informed consent, which,
along with the study protocol and questionnaires, was
What’s new?
• Erectile dysfunction is associated with diabetes; how-
ever, how to use it to identify diabetes cases has not
been studied. The aim of this study was to determine
whether the diagnostic accuracy of four well-known
risk scores for undiagnosed diabetes improved in men
with erectile dysfunction, in comparison to men with-
out this comorbidity.
• Most of the assessed risk scores showed a better
capacity to distinguish between a man with diabetes
and a healthy man when applied to men with erectile
dysfunction.
• These findings, although they need to be verified by
more comprehensive studies, suggest that erectile
dysfunction ascertainment could improve diabetes
screening.
ª 2018 The Authors.
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approved by two institutional review boards: those of the
Universidad Peruana Cayetano Heredia (Lima, Peru) and the
London School of Hygiene and Tropical Medicine (London,
UK).
Results
Study population
A total of 799 men with a mean (SD) age of 48.6 (10.7)
years were included. The prevalence of Type 2 diabetes
was 9.3% (95% CI 7.4–11.5); this represented 74 men, of
whom 48.7% were not aware they had Type 2 diabetes.
Further details of the study population are given in
Table 1.
Type 2 diabetes and erectile dysfunction
Overall, the proportion of men with ED was 7.8% (95% CI
6.1–9.8). There was an association between Type 2 diabetes
and ED (P<0.001; Table 1). Moreover, ED was strongly
associated with Type 2 diabetes in both unadjusted (preva-
lence ratio 3.82, 95% CI 2.40–6.07) and adjusted (preva-
lence ratio 2.71, 95% CI 1.57–4.66) regression models,
signalling that ED occurrence in Type 2 diabetes is indepen-
dent of other clinical characteristics, such as BMI and
hypertension.
Men with ED did not have significantly higher postpran-
dial glucose than men without ED (P=0.319): mean (SD) 6.7
(2.8) mmol/l vs 6.3 (2.3) mmol/l. A cross-tabulation of
impaired glucose tolerance according to oral glucose
Table 1 Socio-demographic and clinical characteristics of the study population according to diabetes status
No diabetes Diabetes P
Age N=724 N=74 <0.001
<40 years 29.1 9.5
40–49 years 28.5 24.3
50–59 years 23.6 44.6
≥60 years 18.8 21.6
Mean (SD) age, years 48.2 (10.7) 52.8 (9.2) <0.001
Assets index N=724 N=74 0.364
Low 31.8 25.7
Middle 35.4 33.8
Top 32.9 40.5
Mean (SD) 245.5 (153.8) 294.9 (181.2) 0.010
Smoking status N=724 N=74 0.639
Non-smoker 74.2 78.4
Occasional smoker 14.8 10.8
Daily smoker 11.1 10.8
Alcohol consumption N=724 N=74 0.080
Never 20.0 31.1
Once or less per month 60.9 54.1
More than once per month 19.1 14.9
Alcohol as per AUDIT N=724 N=74 0.298
Negative 84.7 89.2
Positive 15.3 10.8
Physical activity N=724 N=74 0.157
Low 23.9 33.8
Moderate 31.6 29.7
High 44.5 36.5
Mean (SD) 5056.8 (6239.6) 4099.4 (5859.8) 0.207
BMI N=724 N=74 0.069
<25 kg/m2 33.2 20.3
25–29.9 kg/m2 45.0 51.4
≥30 kg/m2 21.8 28.4
Mean (SD) 27.0 28.1 <0.001
Hypertension N=724 N=74 0.001
No 74.2 55.4
Yes 25.8 44.6
Mean (SD) systolic blood pressure 123.8 (14.4) 130.3 (19.9) <0.001
Depression (PHQ-9) N=724 N=74 0.006
No 99.3 96.0
Yes (score ≥10), n 0.7 4.1
Erectile dysfunction N=724 N=74 <0.001
No 93.9 75.7
Yes 6.1 24.3
AUDIT, Alcohol Use Disorders Identification Test; PHQ-9, nine-item Patient Health Questionnaire.
P values for categorical variables refer to the chi-squared test, while for numerical variables they refer to Student’s t-test.
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tolerance test and ED revealed a worse profile in men with
ED (P<0.001): 59.7% were euglycaemic, 11.3% had
impaired glucose tolerance and 29.0% had Type 2 diabetes;
the respective rates for men without ED were 79.9%, 12.5%
and 7.6%.
Erectile dysfunction for undiagnosed Type 2 diabetes
screening
Because the screening tools were designed for undiagnosed
Type 2 diabetes, men who were aware they had Type 2
diabetes (n=38) were excluded from the following analysis.
The mean scores using the four Type 2 diabetes risk
screening tools assessed were 7.8 (FINDRISC), 8.1 (LA-
FINDRISC), 4.7 (ADA) and 1.5 (Peruvian Risk Score). All
the risk scores, except the one based on ADA criteria,
improved their discrimination accuracy (i.e. had a greater
AUC) when they were applied to men with ED, in compar-
ison to when they were applied to men without ED or overall
(with and without ED together; Fig. 1). The largest increase
was found in the LA-FINDRISC, which had a 76.5% AUC
overall, whilst this figure for men with ED reached up to
90.0% (Fig. 1a). This suggests that ascertaining the presence
of ED before applying a Type 2 diabetes risk score could
enhance the diagnostic accuracy of risk scores.
Discussion
Main findings
The prevalence of ED was higher in men with Type 2
diabetes than in otherwise healthy men. If the ascertainment
of ED was carried out before applying well-known risk
scores for undiagnosed Type 2 diabetes, their diagnostic
performance, based on AUC, would improve in men who
reported ED, in relation to men who did not have this
condition and overall. These findings suggest that screening
for ED in men before screening for Type 2 diabetes could
improve the chances of correctly identifying those at high
risk of Type 2 diabetes.
Results interpretation
Almost one-quarter of men with Type 2 diabetes in the
present study population had ED. This estimate was smaller
than those reported in other studies [3]. The explanation for
this difference could lie in the definition of ED used in the
present study; we based this on a single question whereas
other studies used validated questionnaires to assess ED. In
fact, it has been reported that different ED identification
tools yield different prevalence estimates [3]. Our results are
conservative and warn of a higher prevalence of comorbid
Type 2 diabetes with ED in Peru. In addition to the different
instrument used to define ED, our study population was
younger than that in many other studies addressing the
association between Type 2 diabetes and ED; however, some
studies with even younger populations have also reported a
high prevalence of ED [3]. This further supports the
relevance of the role of ED ascertainment in assessing risk
of Type 2 diabetes.
It has been reported that ED is a Type 2 diabetes-
associated factor [3], with even higher prevalence where
metabolic control is not optimal [13]. In men with Type 2
diabetes who are aware of their condition this could signal
insufficient treatment or low adherence. Notwithstanding, in
men unaware of having Type 2 diabetes, this could hide a
long-lasting illness. This is the most likely situation for the
men in the present study, who did not undergo regular
medical screening or have a high prevalence of Type 2
diabetes risk factors [6]. Identifying men with ED (i.e. men
with long-lasting unknown Type 2 diabetes) could therefore
improve the accuracy of Type 2 diabetes screening methods.
Future studies need to prove, or disprove, this hypothesis in
order for ED, a prevalent associated factor, to help in Type 2
diabetes screening and identification.
Pathways between erectile dysfunction and diabetes
The association between Type 2 diabetes and ED has been
extensively studied and summarized in systematic reviews
pinpointing high ED prevalence in men with diabetes [3,14].
In addition to this epidemiological evidence, a strong case
has been made to support the physiological pathways
between these two conditions [15–18]. Although a compre-
hensive review of these pathways was beyond the scope of
the present study, the possible mechanisms include: (1)
hormonal deficiency (men with diabetes have lower testos-
terone levels); (2) endothelial dysfunction and dearth of nitric
oxide at the penis circulation level, related to oxidative stress,
advanced glycation end products and endothelins; and (3)
impaired blood irrigation to the vasa nervorum at the penis
(cavernous nerve) level.
The main strength of the present study is its assessment of
the outcome variable based on an oral glucose tolerance test.
The main limitation is the evaluation of the exposure
variable based on only one question, whereas most studies
have used validated questionnaires [3]. If this non-differential
misclassification of the exposure of interest had had an effect
on the results, then the point estimates of the regression
model would have been towards the null. This was not the
case because we reported strong associations even in the
adjusted model. Not using a more comprehensive ED
assessment tool could have prevented us from finding more
cases for the stratified analysis; this could explain the wide
CIs. Future studies should verify our results with larger
sample size and using stronger methods to assess ED.
Nevertheless, from a pragmatic point of view, our results
suggest that, even with a simple question, assessment of ED
could improve Type 2 diabetes screening at the population
level.
ª 2018 The Authors.
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FIGURE 1 Area under the receiver-operator curve (ROC; 95% CI) for each assessed diabetes risk score according to erectile dysfunction (ED) status:
(a) LA-FINDRISC, (b) FINDRISC, (c) American Diabetes Association (ADA) score and (d) Peruvian Risk Score.
1542
ª 2018 The Authors.
Diabetic Medicine published by John Wiley & Sons Ltd on behalf of Diabetes UK.
DIABETICMedicine Erectile dysfunction to improve diabetes screening  R.M. Carrillo-Larco et al.
In conclusion, ED is more common in men with Type 2
diabetes than in their otherwise healthy counterparts. It
seems that ED screening, even with one simple question,
before screening for Type 2 diabetes could enhance the odds
of finding a true Type 2 diabetes case.
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